ITINGEN, Switzerland -- (BUSINESS WIRE) --
Harlan Contract Research Services and Bertin Pharma of Montigny-le-Bretonneux, France, signed a strategic partnership to offer comprehensive early drug development services. The companies will offer a wider range of drug discovery and translational medicine services, including expanded profiling and molecule testing, especially in the context of regulatory studies.
Through the alliance, Harlan CRS will strengthen its drug discovery and translational medicine offerings utilizing Bertin Pharma’s expertise in immunology and biomarkers.
“We welcome this agreement. Bertin Pharma’s expertise in the immunological sector is impressive and well-known in the industry,” said Manuela Leone, Harlan CRS president.
“The agreement benefits us strategically and scientifically,” said Ciriaco Maraschiello, Harlan CRS director of strategic initiatives and director of drug discovery and translational medicine. “Together, we will provide the industry the best scientists to increase the likelihood of success for new generation drugs.”
“This partnership will increase our international visibility and allow us to expand services by integrating project management capabilities and expertise,” said Xavier Morge, Bertin Pharma managing director.
“PharmImmune, our joint offer with the French Alternative Energies and Atomic Energy Commission, is an example of an innovation that we will better utilize through our agreement with Harlan CRS,” said Pascal Clayette, Bertin Pharma’s head of immuno-pharmacology.
About Harlan Contract Research Services
Harlan Contract Research Services (CRS), a division of Harlan Laboratories, Inc., is a privately held provider of general and specialty toxicology services to the global chemical, agrochemical and pharmaceutical industries. With laboratory locations in Germany, Spain, Switzerland and the UK, Harlan CRS' focus is on providing customers with services to optimize product development. Please visit www.harlan.com/crs.
About Bertin Pharma
Bertin Pharma is a global solution provider offering R&D outsourcing services along with bioreagent tools in the fields of pharmacy, biotechnologies, cosmetics and nutrition. Through its innovative range of services, Bertin Pharma's comprehensive offerings cover the whole drug development value chain — from discovery to pharmaceutical development. Please visit www.bertinpharma.com or www.bertin.fr.
For inquiries concerning Harlan CRS:
Lea Studer, +1 308-237-5567
For inquiries concerning Bertin Pharma:
Nathalie Feld, +33 1 53 70 94 23
Florence Fombertasse, +33 (0)139 306 225